For example, linc‐ROR could promote chemotherapy tolerance of breast cancer (Chen et al., 2016a), regulate gemcitabine resistance in breast cancer (Chen et al., 2016b), regulate chemoresistance in docetaxel‐resistant lung adenocarcinoma cells (Pan et al., 2017), and contribute to the resistance of pancreatic cancer cells to gemcitabine (Li et al., 2016). Here, LINC-ROR is linked to pancreatic neoplasm.